



**USAID**  
FROM THE AMERICAN PEOPLE



# SUMMARY TABLE OF HIV TREATMENT REGIMENS

## PEDIATRIC AND ADULT NATIONAL TREATMENT GUIDELINES

**AIDSTAR-One**  
AIDS SUPPORT AND TECHNICAL ASSISTANCE RESOURCES

**JANUARY 2011**

This publication was produced by the AIDS Support and Technical Assistance Resources (AIDSTAR-One) Project, Sector 1, Task Order 1, USAID Contract # GHH-I-00-07-00059-00, funded January 31, 2008.



# **SUMMARY TABLE OF HIV TREATMENT REGIMENS**

PEDIATRIC AND ADULT NATIONAL TREATMENT  
GUIDELINES

## **AIDS Support and Technical Assistance Resources Project**

AIDS Support and Technical Assistance Resources, Sector I, Task Order 1 (AIDSTAR-One) is funded by the U.S. Agency for International Development under contract no. GHH-I-00-07-00059-00, funded January 31, 2008. AIDSTAR-One is implemented by John Snow, Inc., in collaboration with Broad Reach Healthcare, Encompass, LLC, International Center for Research on Women, MAP International, Mothers 2 Mothers, Social and Scientific Systems, Inc., University of Alabama at Birmingham, the White Ribbon Alliance for Safe Motherhood, and World Education. The project provides technical assistance services to the Office of HIV/AIDS and USG country teams in knowledge management, technical leadership, program sustainability, strategic planning, and program implementation support.

### **Disclaimer**

Please note that AIDSTAR-One has conducted extensive on-line research and made a concerted effort to contact Ministries of Health (MOH) or responsible parties to access the most current HIV treatment guidelines. The national guidelines posted here are up-to-date, to the best of the project's knowledge, as of July 2010.

On a semiannual basis, AIDSTAR-One will conduct a review of information available online and revisit contact with Ministries of Health to update this database with the most current treatment guidelines. Should any individuals have knowledge of or access to more recent versions of national guidelines please contact us at [info@aidstar-one.com](mailto:info@aidstar-one.com).

For an interactive online version of this table or the most up-to-date listing of National Treatment Guidelines and regimen summaries, visit:  
[www.aidstar-one.com/focus\\_areas/treatment/resources/national\\_treatment\\_guidelines](http://www.aidstar-one.com/focus_areas/treatment/resources/national_treatment_guidelines)

### **AIDSTAR-One**

John Snow, Inc.  
1616 Fort Myer Drive, 11th Floor  
Arlington, VA 22209 USA  
Phone: 703-528-7474  
Fax: 703-528-7480  
E-mail: [info@aidstar-one.com](mailto:info@aidstar-one.com)  
Internet: [aidstar-one.com](http://aidstar-one.com)

# ACRONYMS

3TC	lamivudine
ABC	abacavir
ART	antiretroviral therapy
ARV	antiretroviral
ATV/r	atazanavir/ritonavir
ATZr/r	atazanavir/ritonavir
AZT	zidovudine
CD4	cluster of differentiation 4
CDC	Centers for Disease Control and Prevention
d4T	stavudine
ddI	didanosine
DRV/r	darunavir/ritonavir
EFV	efavirenz
ENF	enfuvirtide
f-APVr/r	fosamprenavir/ritonavir
FPV/r	fosamprenavir/ritonavir
FTC	emtricitabine
IDV	idinavir
IDV/r	idinavir/ritonavir
LIP	lymphocytic interstitial pneumonia
LPV/r	liponavir/ritonavir
MVC	maraviroc
NFV	nelfinavir
NNRTI	non-nucleoside reverse transcriptase inhibitor
NRTI	nucleoside reverse transcriptase inhibitor
NVP	nevirapine
OHL	oral hairy leukoplakia
PI	protease inhibitor
PI/r	protease inhibitor/ritonavir
PMTCT	prevention of mother-to-child transmission

RAL	raltegravir
RTV	ritonavir
SQV/r	saquinavir/ritonavir
TB	tuberculosis
TDF	tenofovir
TLC	total lymphocyte count
TPV/r	tipranavir/ritonavir
WHO	World Health Organization

Country (Year)	Clients	Criteria For Starting ARV Treatment	First Line Regimen	Second Line Regimen	Third Line Regimen
Argentina (2009)	Adults and adolescents	<p><b>All patients with:</b></p> <ul style="list-style-type: none"> <li>CD4 count &lt; 350/mm<sup>3</sup>; <b>or</b></li> <li>A history of AIDS-defining illness or clinically significant symptoms suggesting advanced disease.</li> </ul> <p><b>If CD4 count is &gt; 350/mm<sup>3</sup> but &lt; 500/mm<sup>3</sup>, patient should be considered for ART if:</b></p> <ul style="list-style-type: none"> <li>Viral load &gt; 100,000 copies/mL;</li> <li>There is a drop in CD4 count of &gt; 100/mm<sup>3</sup> per year; <b>or</b></li> <li>Patient has co-morbidities including cardiovascular, renal, or hepatic illness and non-AIDS related cancers</li> </ul>	The choice of first line regimen should be individualized based on potential advantages and disadvantages specific to each patient. Refer to the guidelines for further guidance (pg. 7-18).	The choice of second line regimen should be individualized based on potential advantages and disadvantages specific to each patient. Refer to the guidelines for further guidance (pg. 65-73).	_____
	Infants and children	<p><b>All children &lt; 2 years of age</b></p> <p><b>Children 2 to 5 years of age with:</b></p> <ul style="list-style-type: none"> <li>AIDS-defining illness or clinically significant symptoms (CDC Category B or C);</li> <li>CD4% &lt; 25%; <b>or</b></li> <li>CD4% &gt; 25% but viral load &gt; 100,000 copies/mL</li> </ul> <p><b>Children &gt; 5 years of age* with:</b></p> <ul style="list-style-type: none"> <li>AIDS-defining illness;</li> <li>Clinically significant symptoms (CDC Category B or C); <b>or</b></li> <li>CD4 &lt; 350/mm<sup>3</sup></li> </ul> <p><i>*Consider starting treatment when child is asymptomatic or has mild clinical symptoms.</i></p>	<p><b>PI-based regimens:</b></p> <p>2 NRTIs + LPV/r</p> <p><i>Alternative</i></p> <p><b>&lt; 6 years of age:</b></p> <p>2 NRTIs + NFV</p> <p><b>&gt; 6 years of age:</b></p> <p>2 NRTIs + FPV/r <b>or</b> ATV/r</p> <p>-----</p> <p><b>NNRTI-based regimens:</b></p> <p><b>Children &lt; 3 years of age:</b></p> <p>2 NRTIs + NVP</p> <p><b>Children &gt; 3 years of age:</b></p> <p>2 NRTIs + EFV</p> <p><i>Alternative</i></p> <p>2 NRTIs + NVP</p>	<p><b>For treatment failure with PI regimens:</b></p> <p>2 new NRTIs + PI/r <b>or</b> NNRTI + NNRTI</p> <p>-----</p> <p><b>For treatment failure with NNRTI regimens:</b></p> <p>2 new NRTIs + PI/r (<b>or</b> NNRTI)</p>	_____

Country (Year)	Clients	Criteria For Starting ARV Treatment	First Line Regimen	Second Line Regimen	Third Line Regimen
Bhutan (2008)	Infants and children	<p><b>Children &lt; 18 months of age with:</b></p> <ul style="list-style-type: none"> <li>• CD4% &lt; 25% (1500/mm<sup>3</sup>);</li> <li>• TLC &lt; 3400/mm<sup>3</sup>; <b>or</b></li> <li>• WHO pediatric clinical stage 3 or 4</li> </ul> <p><b>Children 18 months to 5 years of age with:</b></p> <ul style="list-style-type: none"> <li>• CD4% &lt; 15% (500/mm<sup>3</sup>);</li> <li>• TLC &lt; 2300/mm<sup>3</sup>; <b>or</b></li> <li>• WHO pediatric clinical stage 3 or 4</li> </ul> <p><b>Children &gt; 5 years or age with:</b></p> <ul style="list-style-type: none"> <li>• CD4% &lt; 15% (200/mm<sup>3</sup>);</li> <li>• TLC &lt; 1200/mm<sup>3</sup>; <b>or</b></li> <li>• WHO pediatric clinical stage 3 or 4</li> </ul>	AZT + 3TC + EFV <b>or</b> NVP	d4T + 3TC + EFV <b>or</b> NVP	_____
Bolivia (2009)	Adults	<p><b>All patients with:</b></p> <ul style="list-style-type: none"> <li>• WHO clinical stage 1, 2 or 3 with CD4 count &lt; 500/mm<sup>3</sup>; <b>or</b></li> <li>• WHO clinical stage 4</li> </ul>	<p>AZT <b>or</b> d4T* + 3TC + NVP <b>or</b> EFV</p> <p><i>*Limit the use only in the case of AZT toxicity</i></p> <p>-----</p> <p>AZT + 3TC + ddl</p>	<p>3TC <b>or</b> AZT + ddl + IDV/r <b>or</b> LPV/r</p> <p>-----</p> <p>TDF + 3TC + IDV/r <b>or</b> LPV/r</p>	_____
Botswana (2008)	Adults	<p><b>All patients with:</b></p> <ul style="list-style-type: none"> <li>• CD4 count &lt; 250/mm<sup>3</sup>; <b>or</b></li> <li>• WHO clinical stage 3 or 4</li> </ul>	TDF + FTC <b>or</b> 3TC + EFV <b>or</b> NVP	AZT + 3TC + LPV/r	DRV/r + RAL
	Infants and children	<p><b>All infants (&lt; 12 months of age)</b></p> <p><b>Children &lt; 5 years of age:</b> Based on age-related CD4% according to WHO</p> <p><b>Children &gt; 5 years of age with:</b> WHO pediatric clinical stage 3 or 4</p>	d4T <b>or</b> AZT + 3TC + NVP <b>or</b> EFV <b>or</b> LPV/r	ABC + d4T + LPV/r	_____
Brazil (2008)	Adults	<p><b>All patients with:</b></p> <ul style="list-style-type: none"> <li>• CD4 count &lt; 200/mm<sup>3</sup>;</li> <li>• A history of AIDS-defining illness or clinically significant symptoms suggesting advanced disease; <b>or</b></li> <li>• CD4 count &gt; 200/mm<sup>3</sup> and &lt; 350/mm<sup>3</sup> with viral load &gt;100,000 copies/mL</li> </ul>	AZT + 3TC + EFV <b>or</b> LPV/r	ddl <b>or</b> TDF + 3TC + NVP <b>or</b> ATV/r	_____

Country (Year)	Clients	Criteria For Starting ARV Treatment	First Line Regimen	Second Line Regimen	Third Line Regimen
Chile (2005)	Adults (≥ 18 years of age)	<p><b>All patients with:</b></p> <ul style="list-style-type: none"> <li>• CD4 count &lt; 200/mm<sup>3</sup>; <b>or</b></li> <li>• A history of CDC Category C illness, with the exception of pulmonary TB</li> </ul> <p><b>All patients with CD4 count &gt; 200/mm<sup>3</sup> and &lt; 250/mm<sup>3</sup> with one or more of the following:</b></p> <ul style="list-style-type: none"> <li>• CDC Category B illness;</li> <li>• CD4 decrease of 20/mm<sup>3</sup> per month; <b>or</b></li> <li>• Viral load of &gt; 100,000 copies/mL</li> </ul>	<p>AZT <b>or</b> ddl + 3TC + EFV <b>or</b> NVP</p> <p>-----</p> <p>AZT <b>or</b> ddl + 3TC + LPV/r</p>	<p>ABC + 3TC + EFV <b>or</b> NVP</p> <p>-----</p> <p>ABC + 3TC + LPV/r</p> <p>-----</p> <p>ABC <b>or</b> AZT + 3TC + ATV/r</p>	-----
	Infants and children	<p><b>Infants &lt; 3 months of age with:</b></p> <ul style="list-style-type: none"> <li>• Confirmed HIV infection, except CDC Category N or A with high CD4 count and low viral load</li> </ul> <p><b>Infants 3 to 12 months of age with:</b></p> <ul style="list-style-type: none"> <li>• CDC Category C;</li> <li>• WHO pediatric clinical stage 3; <b>or</b></li> <li>• CDC Category B2 if viral load is high and CD4% &lt; 25%</li> </ul> <p><b>Children 1 to 3 years of age with:</b></p> <ul style="list-style-type: none"> <li>• CDC Category C;</li> <li>• WHO pediatric clinical stage 3; <b>or</b></li> <li>• CDC Category B2 if viral load is high and CD4% &lt; 20%</li> </ul> <p><b>Children &gt; 3 years of age with:</b></p> <ul style="list-style-type: none"> <li>• CDC Category C;</li> <li>• WHO pediatric clinical stage 3; <b>or</b></li> <li>• CDC Category B2 if viral load is high and CD4 count is risky</li> </ul>	<p><b>Children &lt; 3 years of age:</b></p> <p>AZT <b>or</b> d4T <b>or</b> ABC + 3TC + NVP <b>or</b> NFV <b>or</b> LPV/r</p> <p>-----</p> <p>AZT + ddl + NVP <b>or</b> NFV <b>or</b> LPV/r</p> <p><b>Children &gt; 3 years of age:</b></p> <p>AZT <b>or</b> d4T <b>or</b> ABC + 3TC + EFV <b>or</b> NFV <b>or</b> LPV/r</p> <p>-----</p> <p>AZT + ddl + EFV <b>or</b> NFV <b>or</b> LPV/r</p>	-----	-----

Country (Year)	Clients	Criteria For Starting ARV Treatment	First Line Regimen	Second Line Regimen	Third Line Regimen
Colombia (2005)	Adults	<p><b>All patients with:</b></p> <ul style="list-style-type: none"> <li>CD4 count &lt; 200/mm<sup>3</sup>; <b>or</b></li> <li>HIV-related symptoms</li> </ul> <p><b>Consider treating patients with:</b></p> <ul style="list-style-type: none"> <li>CD4 count &lt; 250/mm<sup>3</sup>; <b>or</b></li> <li>CD4 count &gt; 250/mm<sup>3</sup> and &lt; 350/mm<sup>3</sup> with a viral load &gt; 100,000 copies/mL</li> </ul>	<p>AZT <b>or</b> d4T <b>or</b> ddl <b>or</b> ABC + 3TC + EFV <b>or</b> NVP</p> <p>-----</p> <p>AZT + 3TC + FPV/r <b>or</b> SQV/r <b>or</b> LPV/r <b>or</b> ATV/r</p>	<p>ABC + ddl + EFV <b>or</b> NVP</p> <p>-----</p> <p>ABC + ddl + FPV/r <b>or</b> SQV/r <b>or</b> LPV/r <b>or</b> ATV/r</p> <p>-----</p> <p>AZT <b>or</b> d4T + ABC + FPV/r <b>or</b> SQV/r <b>or</b> LPV/r <b>or</b> ATV/r</p> <p>-----</p> <p>AZT <b>or</b> d4T + ABC + EFV <b>or</b> NVP</p> <p>-----</p> <p>3TC + ABC + EFV <b>or</b> NVP</p> <p>-----</p> <p>3TC + ABC + FPV/r <b>or</b> SQV/r <b>or</b> LPV/r <b>or</b> ATV/r</p> <p>-----</p> <p>3TC + d4T <b>or</b> ddl + EFV <b>or</b> NVP + LPV/r</p>	-----
Côte d'Ivoire (2005)	Adults	<p><b>All patients with:</b></p> <ul style="list-style-type: none"> <li>CD4 count &lt; 200/mm<sup>3</sup>;</li> <li>CD4 count &lt; 350/mm<sup>3</sup> and CDC Category B; <b>or</b></li> <li>WHO clinical stage 2, 3 or 4, or CDC Category C</li> </ul>	d4T <b>or</b> AZT + 3TC + NVP <b>or</b> EFV	ABC <b>or</b> TDF + ddl + LPV/r <b>or</b> SQV/r <b>or</b> IDV/r	Refer to specialized hospital
	Infants and children	<p><b>Children &lt; 18 months of age with:</b></p> <ul style="list-style-type: none"> <li>WHO pediatric clinical stage 3 or CDC Category C irrespective of CD4%;</li> <li>WHO pediatric clinical stage 1 or 2 with CD4% &lt; 20%</li> </ul> <p><b>Children &gt; 18 months of age with:</b></p> <ul style="list-style-type: none"> <li>CD4% &lt; 15%; <b>or</b></li> <li>WHO pediatric clinical stage 3 or CDC Category C</li> </ul>	d4T <b>or</b> AZT + 3TC + NVP <b>or</b> EFV	ABC + ddl + LPV/r	Refer to specialized hospital

Country (Year)	Clients	Criteria For Starting ARV Treatment	First Line Regimen	Second Line Regimen	Third Line Regimen
Cuba (2009)	Adults	<p><b>All patients with CD4 count &lt; 350/mm<sup>3</sup></b></p> <p><b>Patients with special conditions, including:</b></p> <ul style="list-style-type: none"> <li>• Viral load &gt; 55,000 copies/mL</li> <li>• Co-morbidities such as hepatitis B or C, cirrhosis of the liver, or cancer</li> <li>• Age &gt; 55 years of age</li> </ul>	AZT or d4T + 3TC or ddl + NVP or IDV	Refer to the guidelines for further guidance (pg. 18)	_____
Democratic Republic of Congo (2005)	Adults	<p><b>All patients with:</b></p> <ul style="list-style-type: none"> <li>• CD4 count &lt; 200/mm<sup>3</sup>;</li> <li>• WHO clinical stage 4; <b>or</b></li> <li>• CD4 count &lt; 350/mm<sup>3</sup> at WHO clinical stage 3</li> </ul>	d4T or AZT + 3TC + NVP or EFV	ABC + ddl + LPV/r	_____
	Infants and children	<p><b>Children &lt; 18 months of age with:</b></p> <ul style="list-style-type: none"> <li>• WHO pediatric clinical stage 3 irrespective of CD4%; <b>or</b></li> <li>• WHO pediatric clinical stage 1 or 2 with CD4% &lt; 20%</li> </ul> <p><b>Children &gt; 18 months of age with:</b></p> <ul style="list-style-type: none"> <li>• WHO pediatric clinical stage 3 irrespective of CD4%; <b>or</b></li> <li>• WHO pediatric clinical stage 1 or 2 with CD4% &lt; 15%</li> </ul>	<p><b>Children &lt; 3 years of age:</b></p> <p>AZT + 3TC + NVP</p> <p><b>Children &gt; 3 years of age:</b></p> <p>d4T + 3TC + NVP</p>	ABC + ddl + NFV	_____
Dominican Republic (2004)	Adults	<p><b>All patients with:</b></p> <ul style="list-style-type: none"> <li>• CD4 count &lt; 200/mm<sup>3</sup> and WHO clinical stage 1, 2 or 3;</li> <li>• WHO clinical stage 4;</li> <li>• Rapid CD4 decline (&gt; 20/mm<sup>3</sup>/month) and viral load &gt; 100,000 copies/mL; <b>or</b></li> <li>• WHO clinical stage 2 or 3 and TLC &lt; 1200/mm<sup>3</sup></li> </ul>	AZT + 3TC + EFV or NVP	AZT + 3TC + IDV/r	Use of four or more ARVs. See guidelines for further guidance (pg. 64-67).

Country (Year)	Clients	Criteria For Starting ARV Treatment	First Line Regimen	Second Line Regimen	Third Line Regimen
Dominican Republic (2004)	Infants and children (< 13 years of age)	<p><b>Children &lt; 18 months of age with:</b></p> <ul style="list-style-type: none"> <li>• WHO pediatric clinical stage 3; <b>or</b></li> <li>• WHO pediatric clinical stage 1 or 2 and CD4% &lt; 20%</li> </ul> <p><b>Children &gt; 18 months and &lt; 13 years of age with:</b></p> <ul style="list-style-type: none"> <li>• WHO pediatric clinical stage 3; <b>or</b></li> <li>• WHO pediatric clinical stage 1 or 2 and CD4 % &lt; 15%</li> </ul>	<p><b>Children weighing &lt; 10 kg:</b></p> <p>AZT + 3TC + NVP</p> <p><b>Children weighing &gt; 10 kg:</b></p> <p>AZT + 3TC + EFV</p>	AZT + 3TC + LPV/r	_____
Ecuador (2007)	Adults and adolescents	<p><b>All patients with:</b></p> <ul style="list-style-type: none"> <li>• CD4 count &lt; 200/mm<sup>3</sup>;</li> <li>• AIDS-defining illness or CDC Category B or C symptoms; <b>or</b></li> <li>• CD4 count &gt; 200/mm<sup>3</sup> but &lt; 350/mm<sup>3</sup> with a viral load &gt; 100,000 copies/mL</li> </ul>	<p>AZT <b>or</b> ddl <b>or</b> ABC <b>or</b> d4T + 3TC + EFV</p> <p>-----</p> <p>AZT <b>or</b> d4T + 3TC + NVP</p> <p>-----</p> <p>AZT + 3TC + SQV/r <b>or</b> LPV/r <b>or</b> ATV/r</p> <p>-----</p> <p>TDF + FTC + NNRTI <b>or</b> PI</p>	Refer to the guidelines for further guidance (pg. 42-43)	_____
Ethiopia (2008)	Adults	<p><b>All patients with:</b></p> <ul style="list-style-type: none"> <li>• CD4 count &lt; 200/mm<sup>3</sup>;</li> <li>• WHO clinical stage 4; <b>or</b></li> <li>• CD4 count &lt; 350/mm<sup>3</sup> at WHO clinical stage 3</li> </ul>	<p>d4T <b>or</b> AZT + 3TC + NVP <b>or</b> EFV</p> <p>-----</p> <p>ABC + 3TC + AZT</p>	<p>ABC + 3TC + LPV/r <b>or</b> ATV/r</p> <p>-----</p> <p>AZT + ABC + LPV/r <b>or</b> ATV/r</p> <p>-----</p> <p>TDF + 3TC + LPV/r <b>or</b> ATV/r</p> <p>-----</p> <p>ABC + ddl + LPV/r</p> <p>-----</p> <p>EFV <b>or</b> NVP + LPV/r <b>or</b> ATV/r</p>	_____
	Infants and children	<p><b>All infants (&lt; 12 months of age)</b></p> <p><b>Children from 1 to 5 years of age with:</b></p> <ul style="list-style-type: none"> <li>• WHO pediatric clinical stage 3 or 4; <b>or</b></li> <li>• WHO pediatric clinical stage 1 or 2 at CD4% &lt; 20%</li> </ul> <p><b>Children &gt;5 years of age with:</b></p> <ul style="list-style-type: none"> <li>• CD4% &lt; 15%</li> </ul>	<p>d4T <b>or</b> AZT + 3TC + NVP <b>or</b> EFV <b>or</b> LPV/r</p>	ABC + ddl + LPV/r <b>or</b> NFV	_____

Country (Year)	Clients	Criteria For Starting ARV Treatment	First Line Regimen	Second Line Regimen	Third Line Regimen
Ghana (2005)	Adults	<b>All patients with:</b> <ul style="list-style-type: none"> <li>CD4 count &lt; 250/mm<sup>3</sup>; <b>or</b></li> <li>WHO clinical stage 3 or 4</li> </ul>	d4T <b>or</b> AZT + 3TC + NVP <b>or</b> EFV	ABC + ddl + LPV/r <b>or</b> SQV/r <b>or</b> NFV	_____
	Infants and Children	<b>Children &lt; 18 months of age with:</b> <ul style="list-style-type: none"> <li>WHO pediatric clinical stage 3 or 4 irrespective of CD4%; <b>or</b></li> <li>WHO pediatric clinical stage 2 with CD4% &lt; 20%</li> </ul> <b>Children &gt; 18 months of age with:</b> <ul style="list-style-type: none"> <li>WHO pediatric clinical stage 3 or 4 irrespective of CD4%; <b>or</b></li> <li>CD4% &lt; 15%</li> </ul>	d4T <b>or</b> AZT + 3TC + NVP <b>or</b> EFV	ABC + ddl + SQV/r <b>or</b> NFV	_____
Guyana (2006)	Adults	<b>All patients with:</b> <ul style="list-style-type: none"> <li>CD4 count &lt; 350/mm<sup>3</sup> irrespective of WHO or CDC staging; <b>or</b></li> <li>WHO clinical stage 3 or 4 or CDC stage B or C (symptomatic disease) irrespective of CD4 count</li> </ul>	d4T <b>or</b> AZT + 3TC + NVP <b>or</b> EFV ----- TDF + FTC <b>or</b> 3TC + NVP	TDF + FTC <b>or</b> 3TC + LPV/r ----- TDF + AZT + FTC <b>or</b> 3TC + LPV/r	_____
	Infants and children	<b>Infants &lt; 12 months of age with:</b> <ul style="list-style-type: none"> <li>WHO pediatric clinical stage 3 or 4 irrespective of CD4%; <b>or</b></li> <li>WHO pediatric clinical stage 1 or 2 with CD4% &lt; 25%</li> </ul> <b>Children from 1 to 5 years of age with:</b> <ul style="list-style-type: none"> <li>WHO pediatric clinical stage 3 or 4 irrespective of CD4%; <b>or</b></li> <li>WHO pediatric clinical stage 1 or 2 with CD4% &lt; 20%</li> </ul> <b>Children &gt; 5 years of age with:</b> <ul style="list-style-type: none"> <li>WHO pediatric clinical stage 3 or 4 irrespective of CD4 count or %; <b>or</b></li> <li>CD4 count &lt; 350/mm<sup>3</sup></li> </ul>	AZT + 3TC + NVP <b>or</b> EFV	ABC + ddl + LPV/r	_____

Country (Year)	Clients	Criteria For Starting ARV Treatment	First Line Regimen	Second Line Regimen	Third Line Regimen
Haiti (2008)	Adults and adolescents	<p><b>All patients with:</b></p> <ul style="list-style-type: none"> <li>CD4 count &lt; 200/mm<sup>3</sup>; <b>or</b></li> <li>WHO clinical stage 3 or 4</li> </ul> <p><b>Those with a CD4 count &gt; 200/mm<sup>3</sup> but &lt; 350/mm<sup>3</sup> may be considered for treatment</b></p>	<p>TDF + FTC + EFV <b>or</b> NVP</p> <p>-----</p> <p>AZT <b>or</b> d4T + 3TC + EFV <b>or</b> NVP</p>	<p>AZT + 3TC + LPV/r</p> <p>-----</p> <p>TDF + FTC + LPV/r</p>	_____
India (2007)	Adults and adolescents	<p><b>All patients with:</b></p> <ul style="list-style-type: none"> <li>CD4 count &lt; 200/mm<sup>3</sup>; <b>or</b></li> <li>WHO clinical stage 4</li> </ul> <p><b>Those with a CD4 count &gt; 200/mm<sup>3</sup> but &lt; 350/mm<sup>3</sup> at WHO clinical stage 3 may be considered for treatment</b></p>	d4T <b>or</b> AZT + 3TC + NVP <b>or</b> EFV	ABC + ddl + LPV/r <b>or</b> SQV/r <b>or</b> NFV	_____
India (2006)	Infants and children	<p><b>Clinical Markers</b></p> <p><b>Infants &lt; 12 months of age with:</b></p> <ul style="list-style-type: none"> <li>WHO pediatric clinical stage 3 or 4</li> </ul> <p><b>Children &gt; 12 months of age with:</b></p> <ul style="list-style-type: none"> <li>WHO pediatric clinical stage 4; <b>or</b></li> <li>WHO pediatric clinical stage 3, but use CD4 as a guide for children with TB, LIP, OHL or thrombocytopenia</li> </ul> <p><b>Immunological Markers</b></p> <p><b>Infants &lt; 11 months of age with:</b></p> <ul style="list-style-type: none"> <li>CD4 count &lt; 1500/mm<sup>3</sup> (25%)</li> </ul> <p><b>Children 12 to 35 months of age with:</b></p> <ul style="list-style-type: none"> <li>CD4 count &lt; 7500/mm<sup>3</sup> (20%)</li> </ul> <p><b>Children 36 to 59 months of age with:</b></p> <ul style="list-style-type: none"> <li>CD4 count &lt; 350/mm<sup>3</sup> (15%)</li> </ul> <p><b>Children &gt; 5 years of age with:</b></p> <ul style="list-style-type: none"> <li>CD4 count &lt; 200/mm<sup>3</sup>; <b>or</b></li> <li>CD4 count &lt; 350/mm<sup>3</sup> at WHO pediatric clinical stage 3</li> </ul>	d4T <b>or</b> AZT + 3TC + NVP <b>or</b> EFV	ddl + ABC <b>or</b> AZT <b>or</b> EFV <b>or</b> NVP + LPV/r <b>or</b> SQV/r <b>or</b> NFV	_____

Country (Year)	Clients	Criteria For Starting ARV Treatment	First Line Regimen	Second Line Regimen	Third Line Regimen
Kenya (2005)	Adults and adolescents	<b>All patients with:</b> <ul style="list-style-type: none"> <li>• CD4 count &lt; 200/mm<sup>3</sup>;</li> <li>• WHO clinical stage 4; <b>or</b></li> <li>• CD4 count &lt; 350/mm<sup>3</sup> at WHO clinical stage 3</li> </ul>	d4T <b>or</b> AZT + 3TC + NVP <b>or</b> EFV	ABC + ddl + LPV/r <b>or</b> SQV/r <b>or</b> NFV	_____
	Infants and children	<b>Children &lt; 18 months of age with:</b> <ul style="list-style-type: none"> <li>• WHO pediatric clinical stage 3 irrespective of CD4%; <b>or</b></li> <li>• WHO pediatric clinical stage 1 or 2 with CD4% &lt; 20%</li> </ul> <b>Children &gt; 18 months of age with:</b> <ul style="list-style-type: none"> <li>• CD4% &lt; 15%; <b>or</b></li> <li>• WHO pediatric clinical stage 3</li> </ul>	<b>Children not exposed previously to NVP for PMTCT</b>  <b>Children &lt; 3 years of age, weighing &lt; 10 kg:</b>  AZT + 3TC + NVP  <b>Children &gt; 3 years of age, weighing &gt; 10 kg:</b>  AZT + 3TC + NVP <b>or</b> EFV ----- <b>Children previously exposed to NVP for PMTCT</b>  <b>All ages:</b>  AZT + 3TC + LPV/r	ABC + ddl + LPV/r	_____
Malawi (2008)	Adults and adolescents	<b>All patients with:</b> <ul style="list-style-type: none"> <li>• CD4 count &lt; 250/mm<sup>3</sup>;</li> <li>• WHO clinical stage 3 or 4; <b>or</b></li> <li>• TLC &lt; 1200/mm<sup>3</sup> at WHO clinical stage 3</li> </ul>	d4T <b>or</b> AZT + 3TC + NVP <b>or</b> EFV	AZT + 3TC + TDF + LPV/r	_____
	Infants and children	<b>Children &lt; 18 months of age with:</b> <ul style="list-style-type: none"> <li>• WHO pediatric clinical stage 4; <b>or</b></li> <li>• Two or more of: oral candidiasis, severe pneumonia, severe sepsis</li> </ul> <b>Children &gt; 18 months of age with:</b> <ul style="list-style-type: none"> <li>• CD4% &lt; 15%; <b>or</b></li> <li>• WHO pediatric clinical stage 3 or 4</li> </ul>	d4T <b>or</b> AZT + 3TC + NVP <b>or</b> EFV	ABC + ddl + LPV/r	_____

Country (Year)	Clients	Criteria For Starting ARV Treatment	First Line Regimen	Second Line Regimen	Third Line Regimen
Mexico (2009)	Adults (>13 years of age)	<p><b>All patients with:</b></p> <ul style="list-style-type: none"> <li>CD4 count &lt; 350/mm<sup>3</sup>; <b>or</b></li> <li>AIDS-defining illness, severe opportunistic infections, chronic active hepatitis B or nephropathy</li> </ul> <p><b>Treatment is optional for patients with CD4 count between 350/mm<sup>3</sup> and 500/ mm<sup>3</sup> with:</b></p> <ul style="list-style-type: none"> <li>Viral load &gt; 100,000 copies/mL;</li> <li>Annual CD4 count decline of 50-100/mm<sup>3</sup>;</li> <li>Patient age &gt; 55 years of age; <b>or</b></li> <li>Co-infection with hepatitis C</li> </ul>	<p>TDF + FTC + EFV <b>or</b> ATZr/r <b>or</b> f-APVr/r <b>or</b> LPV/r <b>or</b> SQV/r</p> <p>-----</p> <p>ABC + 3TC + EFV <b>or</b> ATZr/r <b>or</b> f-APVr/r <b>or</b> LPV/r <b>or</b> SQV/r</p>	<p>AZT <b>or</b> TDF + ABC + ddl + EFV <b>or</b> ATZr/r <b>or</b> f-APVr/r <b>or</b> LPV/r <b>or</b> SQV/r <b>or</b> DRV/r <b>or</b> TPV/r</p> <p>-----</p> <p>TDF + AZT <b>or</b> 3TC <b>or</b> FTC + EFV <b>or</b> ATZr/r <b>or</b> f-APVr/r <b>or</b> LPV/r <b>or</b> SQV/r <b>or</b> DRV/r <b>or</b> TPV/r</p> <p>-----</p> <p>ABC + ddl <b>or</b> 3TC <b>or</b> FTC + EFV <b>or</b> ATZr/r <b>or</b> f-APVr/r <b>or</b> LPV/r <b>or</b> SQV/r <b>or</b> DRV/r <b>or</b> TPV/r</p>	MVC, RAL, ENF. See guidelines for further guidance (pg. 22-27).
	Infants and children (< 13 years of age)	<p><b>Infants (&lt; 12 months of age) with:</b></p> <ul style="list-style-type: none"> <li>CDC Category A, B or C; <b>or</b></li> <li>Evidence of immunosuppression</li> </ul> <p><b>All children 1 to 13 years of age with:</b></p> <ul style="list-style-type: none"> <li>CDC Category C;</li> <li>CDC Category N, A, or B with a single episode of severe bacterial infection or lymphocytic interstitial pneumonitis</li> <li>CDC Category B and viral load &gt; 100,000 copies/mL</li> </ul>	<p><b>Infants (&lt; 1 year of age):</b></p> <p>2 NRTIs + NFV <b>or</b> LPV/r* <b>or</b> RTV</p> <p><i>*Not in infants &lt; 6 months</i></p> <p>-----</p> <p>2 NRTIs + NVP</p> <p><b>Children 1 to 13 years of age:</b></p> <p>AZT + 3TC <b>or</b> ddl + LPV/r <b>or</b> RTV <b>or</b> NFV</p> <p>-----</p> <p>d4T + 3TC <b>or</b> FTC + LPV/r <b>or</b> RTV <b>or</b> NFV</p>	<p>TDF + ABC + LPV/r <b>or</b> RTV <b>or</b> NFV</p> <p>-----</p> <p>ABC <b>or</b> AZT <b>or</b> d4T* + 3TC <b>or</b> FTC <b>or</b> ddl + LPV/r <b>or</b> RTV <b>or</b> NFV</p> <p><i>*In case of toxicity to AZT</i></p>	-----
Mozambique (2006)	Adults and adolescents	<p><b>All patients with:</b></p> <ul style="list-style-type: none"> <li>CD4 count &lt; 200/mm<sup>3</sup> at WHO clinical stage 1 or 2</li> <li>CD4 count &lt; 350/mm<sup>3</sup> at WHO clinical stage 3; <b>or</b></li> <li>WHO clinical stage 4</li> </ul>	d4T <b>or</b> AZT <b>or</b> ddl + 3TC + NVP	AZT <b>or</b> d4T + ddl + NFV	-----
Namibia (2003)	Adults and adolescents	<p><b>All patients with:</b></p> <ul style="list-style-type: none"> <li>CD4 count &lt; 200/mm<sup>3</sup>; <b>or</b></li> <li>WHO clinical stage 4</li> </ul>	d4T <b>or</b> AZT + 3TC + NVP <b>or</b> EFV	d4T <b>or</b> AZT + 3TC <b>or</b> ddl + LPV/r <b>or</b> IDV/r	-----

Country (Year)	Clients	Criteria For Starting ARV Treatment	First Line Regimen	Second Line Regimen	Third Line Regimen
Namibia (2003)	Infants and children	<p><b>Children &lt; 8 years of age with:</b></p> <ul style="list-style-type: none"> <li>WHO pediatric clinical stage 3 irrespective of CD4%; <b>or</b></li> <li>WHO pediatric clinical stage 1 or 2 with CD4% &lt; 20%</li> </ul> <p><b>Children &gt; 8 years of age with:</b></p> <ul style="list-style-type: none"> <li>CD4 count &lt; 200/mm<sup>3</sup></li> </ul>	AZT + 3TC + NVP	ddl + d4T + LPV/r	_____
Nepal (2003)	Adults	<p><b>All patients with:</b></p> <ul style="list-style-type: none"> <li>CD4 count &lt; 200/mm<sup>3</sup>;</li> <li>WHO clinical stage 4; <b>or</b></li> <li>TLC &lt; 1200/mm<sup>3</sup> at WHO clinical stage 2 or 3</li> </ul>	AZT + 3TC + EFV <b>or</b> NVP	PI/r (IDV/r, LPV/r, SQV/r) + d4T + ddl	_____
	Infants and children	<p><b>Children &lt; 18 months of age</b> <b>With positive virologic test and:</b></p> <ul style="list-style-type: none"> <li>CD4% &lt; 20% at WHO pediatric clinical stage 1 or 2; <b>or</b></li> <li>WHO pediatric clinical stage 3</li> </ul> <p><b>With no virologic test and:</b></p> <ul style="list-style-type: none"> <li>CD4% &lt; 20% at WHO pediatric clinical stage 3</li> </ul> <p><b>Children ≥ 18 months of age with:</b></p> <ul style="list-style-type: none"> <li>CD4% &lt; 15% at WHO pediatric clinical stage 1 or 2; <b>or</b></li> <li>WHO pediatric clinical stage 3</li> </ul>	<p>AZT + 3TC + NVP (or EFV if child is ≥ 3 years of age or ≥ 10kg)</p> <p>-----</p> <p><b>Preferred if concomitant anti-tuberculosis therapy is being received:</b></p> <p>AZT + 3TC + ABC</p>	<p>d4T + ddl + LPV/r <b>or</b> NFV</p> <p>-----</p> <p>d4T + ddl + LPV/r <b>or</b> NFV <b>or</b> NVP (or EFV if child is ≥ 3 years of age or ≥ 10kg)</p>	_____
Nicaragua (2009)	Adults	<p><b>All patients with:</b></p> <ul style="list-style-type: none"> <li>CD4 count &lt; 350/mm<sup>3</sup>;</li> <li>AIDS-defining illness or symptoms of advanced disease (CDC Category B or C), hepatitis B or HIV-associated nephropathy; <b>or</b></li> <li>CD4 count &gt; 350/mm<sup>3</sup> and viral load &gt; 100,000 copies/mL</li> </ul>	<p><b>CD4 count &gt; 200/mm<sup>3</sup>:</b></p> <p>AZT + 3TC + EFV <b>or</b> NVP</p> <p>-----</p> <p>TDF + FTC <b>or</b> 3TC + EFV <b>or</b> NVP</p> <p><b>CD4 count &lt; 200/mm<sup>3</sup>:</b></p> <p>AZT + 3TC + LPV/r</p> <p>-----</p> <p>TDF + FTC + LPV/r</p>	<p>TDF <b>or</b> AZT + ABC + LPV/r <b>or</b> ATV/r <b>or</b> SQV/r</p> <p>-----</p> <p>TDF + AZT <b>or</b> 3TC <b>or</b> FTC + LPV/r <b>or</b> ATV/r <b>or</b> SQV/r</p> <p>-----</p> <p>2 NRTIs + DRV/r <b>or</b> TPV/r</p>	<p>TDF + ddl <b>or</b> ABC + LPV/r <b>or</b> ATV/r <b>or</b> SQV/r</p> <p>-----</p> <p>AZT <b>or</b> ABC + ddl + LPV/r <b>or</b> ATV/r <b>or</b> SQV/r</p> <p>-----</p> <p>ABC <b>or</b> ddl + 3TC <b>or</b> FTC + LPV/r <b>or</b> ATV/r <b>or</b> SQV/r</p> <p>-----</p> <p>2 NRTIs + DRV/r <b>or</b> TPV/r</p>

Country (Year)	Clients	Criteria For Starting ARV Treatment	First Line Regimen	Second Line Regimen	Third Line Regimen
Nigeria (2007)	Adults and adolescents	<b>All patients with:</b> <ul style="list-style-type: none"> <li>CD4 count &lt; 200/mm<sup>3</sup> at WHO clinical stage 1 or 2;</li> <li>WHO clinical stage 4; <b>or</b></li> <li>CD4 count &lt; 350/mm<sup>3</sup> at WHO clinical stage 3</li> </ul>	AZT <b>or</b> TDF + 3TC <b>or</b> FTC + NVP <b>or</b> EFV	TDF <b>or</b> ddI <b>or</b> ABC + 3TC <b>or</b> FTC + LPV/r	_____
	Infants and children	<b>Children &lt; 5 years of age:</b> Follow age-related CD4% according to WHO	AZT <b>or</b> d4T + 3TC <b>or</b> FTC + NVP	ABC <b>or</b> AZT + 3TC + LPV/r <b>or</b> IDV	_____
Pakistan (2005)	Adults and adolescents	<b>If CD4 testing is available:</b> <ul style="list-style-type: none"> <li>CD4 count &lt; 200/mm<sup>3</sup>;</li> <li>WHO clinical stage 4; <b>or</b></li> <li>Consider treatment when CD4 count &lt; 350/mm<sup>3</sup> and WHO clinical stage 3</li> </ul> <b>If CD4 testing is not available:</b> <ul style="list-style-type: none"> <li>TLC &lt; 1200/mm<sup>3</sup> at WHO clinical stage 2; <b>or</b></li> <li>WHO clinical stage 3 or 4</li> </ul>	AZT + 3TC + NVP	TDF <b>or</b> ABC + ddI + NFV	_____
Panama (2007)	Adults and adolescents	<b>All patients with:</b> <ul style="list-style-type: none"> <li>CD4 count &lt; 350/mm<sup>3</sup>; <b>or</b></li> <li>AIDS-defining illness or symptoms of advanced disease</li> </ul>	AZT + 3TC + EFV ----- FTC + TDF + EFV ----- ddI <b>or</b> d4T + 3TC + EFV	AZT + 3TC + LPV/r <b>or</b> ATV/r <b>or</b> SQV/r <b>or</b> IDV/r	_____

Country (Year)	Clients	Criteria For Starting ARV Treatment	First Line Regimen	Second Line Regimen	Third Line Regimen
Panama (2007)	Infants and children (< 13 years of age)	<p><b>All infants (&lt; 12 months of age)</b></p> <p><b>Children 1 to 4 years of age with:</b></p> <ul style="list-style-type: none"> <li>• CD4% &lt; 20%; <b>or</b></li> <li>• AIDS-defining illness or symptoms of advanced disease</li> </ul> <p><b>Children 4 to 12 years of age with:</b></p> <ul style="list-style-type: none"> <li>• CD4% &lt; 15%; <b>or</b></li> <li>• AIDS-defining illness or symptoms of advanced disease</li> </ul> <p><b>Children 12 to 13 years of age with:</b></p> <ul style="list-style-type: none"> <li>• CD4 count &lt; 200/mm<sup>3</sup>;</li> <li>• AIDS-defining illness or symptoms of advanced disease; <b>or</b></li> <li>• Consider treatment if CD4 count &gt; 200/mm<sup>3</sup> and ≤ 350/mm<sup>3</sup> with viral load &lt; 100,000 copies/mL</li> </ul>	<p><b>Children &lt; 3 years of age:</b></p> <p>AZT + 3TC <b>or</b> FTC + LPV/r <b>or</b> NFV</p> <p>-----</p> <p>ddl <b>or</b> d4T + 3TC <b>or</b> FTC + LPV/r <b>or</b> NFV</p> <p><b>Children &gt; 3 years of age:</b></p> <p>AZT + 3TC + EFV <b>or</b> LPV/r</p>	_____	_____
Papua New Guinea (2003)	Adults and adolescents	<p><b>All patients with:</b></p> <ul style="list-style-type: none"> <li>• CD4 count &lt; 200/mm<sup>3</sup>;</li> <li>• WHO clinical stage 3 or 4; <b>or</b></li> <li>• WHO clinical stage 2 or 3 with TLC &lt; 1200/mm<sup>3</sup></li> </ul>	d4T <b>or</b> AZT + 3TC + NVP	ABC + ddl + LPV/r <b>or</b> SQV/r <b>or</b> NFV	_____
	Infants and children	<p><b>Children &lt; 18 months of age with:</b></p> <ul style="list-style-type: none"> <li>• WHO pediatric clinical stage 3 irrespective of CD4%; <b>or</b></li> <li>• WHO pediatric clinical stage 1 or 2 with CD4% &lt; 20%</li> </ul> <p><b>Children &gt; 18 months of age with:</b></p> <ul style="list-style-type: none"> <li>• WHO pediatric clinical stage 3 irrespective of CD4%; <b>or</b></li> <li>• CD4% &lt; 15%</li> </ul>	d4T <b>or</b> AZT + 3TC + NVP <b>or</b> EFV	ABC + ddl + LPV/r <b>or</b> SQV/r <b>or</b> NFV	_____
Rwanda (2007)	Adults and adolescents	<p><b>All patients with:</b></p> <ul style="list-style-type: none"> <li>• CD4 count &lt; 350/mm<sup>3</sup>; <b>or</b></li> <li>• WHO clinical stage 4</li> </ul>	d4T <b>or</b> TDF <b>or</b> AZT + 3TC + NVP <b>or</b> EFV	ABC <b>or</b> AZT <b>or</b> d4T + 3TC + LPV/r <b>or</b> EFV	_____

Country (Year)	Clients	Criteria For Starting ARV Treatment	First Line Regimen	Second Line Regimen	Third Line Regimen
Rwanda (2007)	Infants and children	<p><b>Infants &lt; 11 months of age with:</b></p> <ul style="list-style-type: none"> <li>CD4 count &lt; 1500/mm<sup>3</sup> (25%)</li> </ul> <p><b>Children 12 to 35 months of age with:</b></p> <ul style="list-style-type: none"> <li>CD4 count &lt; 7500/mm<sup>3</sup> (20%)</li> </ul> <p><b>Children 36 to 59 months of age with:</b></p> <ul style="list-style-type: none"> <li>CD4 count &lt; 350/mm<sup>3</sup> (15%)</li> </ul> <p><b>Children &gt; 5 years of age with:</b></p> <ul style="list-style-type: none"> <li>CD4 count &lt; 350/mm<sup>3</sup> at WHO pediatric clinical stage 1, 2 or 3; <b>or</b></li> <li>WHO pediatric clinical stage 4</li> </ul>	d4T <b>or</b> AZT + 3TC + NVP	ddl + ABC + LPV/r	_____
Senegal	Adults and adolescents	<p><b>All patients with:</b></p> <ul style="list-style-type: none"> <li>CD4 count ≤ 200/mm<sup>3</sup>;</li> <li>CDC Category B and CD4 count ≤ 350/mm<sup>3</sup>; <b>or</b></li> <li>CDC Category C</li> </ul>	The choice of first line regimen should be individualized based on potential advantages and disadvantages specific to each patient. Refer to the guidelines for further guidance.	The choice of first line regimen should be individualized based on potential advantages and disadvantages specific to each patient. Refer to the guidelines for further guidance.	_____
South Africa (2010)	Adults and adolescents	<p><b>All patients with:</b></p> <ul style="list-style-type: none"> <li>CD4 count ≤ 200/mm<sup>3</sup>;</li> <li>WHO clinical stage 4;</li> <li>CD4 count ≤ 350/mm<sup>3</sup> and coinfecting with TB; <b>or</b></li> <li>MDR <b>or</b> XDR TB (multidrug-resistant <b>or</b> extensively drug-resistant tuberculosis)</li> </ul>	TDF + 3TC <b>or</b> FTC + EFV <b>or</b> NVP	AZT + 3TC + LPV/r	_____
	Infants and children	<p><b>All infants (&lt; 12 months of age)</b></p> <p><b>Children 12 months to 5 years of age with:</b></p> <ul style="list-style-type: none"> <li>CD4% ≤ 25% (750/mm<sup>3</sup>); <b>or</b></li> <li>WHO pediatric clinical stage 3 <b>or</b> 4</li> </ul> <p><b>Children &gt; 5 years of age with:</b></p> <ul style="list-style-type: none"> <li>CD4 count &lt; 350/mm<sup>3</sup>; <b>or</b></li> <li>WHO pediatric clinical stage 3 <b>or</b> 4</li> </ul>	<p><b>Children &lt; 3 years of age <b>or</b> weighing &lt; 10kg:</b></p> <p>ABC + 3TC + LPV/r</p> <p><b>Children &gt; 3 years of age <b>and</b> weighing &gt; 10kg:</b></p> <p>ABC + 3TC + EFV</p>	_____	_____

Country (Year)	Clients	Criteria For Starting ARV Treatment	First Line Regimen	Second Line Regimen	Third Line Regimen
Swaziland (2006)	Adults and adolescents	<b>All patients with:</b> <ul style="list-style-type: none"> <li>CD4 count &lt; 200/mm<sup>3</sup>;</li> <li>WHO clinical stage 4; <b>or</b></li> <li>CD4 count &lt; 350/mm<sup>3</sup> at WHO clinical stage 3</li> </ul>	AZT <b>or</b> d4T + 3TC + NVP <b>or</b> EFV	ddl <b>or</b> TDF + ABC + LPV/r	_____
	Infants and children	<b>All children with:</b> <ul style="list-style-type: none"> <li>WHO pediatric clinical stage 3 or 4 irrespective of CD4 count or percentage; <b>or</b></li> <li>WHO pediatric clinical stage 1 or 2, if the CD4 immunological stage is "severe"</li> </ul>	d4T <b>or</b> AZT + 3TC + NVP	ABC + ddl + LPV/r	_____
Tanzania (2005)	Adults and adolescents	<b>All patients with:</b> <ul style="list-style-type: none"> <li>CD4 count ≤ 200/mm<sup>3</sup>;</li> <li>WHO clinical stage 4; <b>or</b></li> <li>CD4 count ≤ 350/mm<sup>3</sup> at WHO clinical stage 3</li> </ul>	d4T <b>or</b> AZT + 3TC + NVP <b>or</b> EFV	ABC + ddl + LPV/r	_____
	Infants and children	<b>Children &lt; 18 months of age with:</b> <ul style="list-style-type: none"> <li>WHO pediatric clinical stage 3 or 4 irrespective of CD4%; <b>or</b></li> <li>WHO pediatric clinical stage 1 or 2 with CD4% &lt; 20%</li> </ul> <b>Children &gt; 18 months of age with:</b> <ul style="list-style-type: none"> <li>WHO pediatric clinical stage 3 or 4 irrespective of CD4%; <b>or</b></li> <li>WHO pediatric clinical stage 1 or 2 with CD4% &lt; 15%</li> </ul>	<b>Children &lt; 3 years of age:</b> AZT + 3TC + NVP  <b>Children &gt; 3 years of age:</b> AZT + 3TC + EFV <b>or</b> NVP	ABC + ddl + LPV/r <b>or</b> NFV	_____
Uganda (2008)	Adults and adolescents	<b>All patients with:</b> <ul style="list-style-type: none"> <li>CD4 count &lt; 250/mm<sup>3</sup>;</li> <li>WHO clinical stage 4; <b>or</b></li> <li>CD4 count &lt; 350/mm<sup>3</sup> and at WHO clinical stage 3 or co-infected with TB</li> </ul>	d4T <b>or</b> AZT <b>or</b> TDF + 3TC <b>or</b> FTC + NVP <b>or</b> EFV	ABC <b>or</b> AZT + ddl + LPV/r ----- TDF + 3TC <b>or</b> FTC + LPV/r	_____

<b>Country (Year)</b>	<b>Clients</b>	<b>Criteria For Starting ARV Treatment</b>	<b>First Line Regimen</b>	<b>Second Line Regimen</b>	<b>Third Line Regimen</b>
<b>Uganda (2008)</b>	<b>Infants and children</b>	<p><b>All infants (&lt; 12 months of age)</b></p> <p><b>Children 12 to 36 months of age with:</b></p> <ul style="list-style-type: none"> <li>• CD4% &lt; 20% or CD4 count &lt; 750/mm<sup>3</sup></li> </ul> <p><b>Children 36 to 59 months of age with:</b></p> <ul style="list-style-type: none"> <li>• CD4% &lt; 20% or CD4 count &lt; 350/mm<sup>3</sup></li> </ul> <p><b>Children &gt; 5 years of age with:</b></p> <ul style="list-style-type: none"> <li>• CD4% &lt; 15% or CD4 count &lt; 250/mm<sup>3</sup></li> </ul>	d4T <b>or</b> AZT + 3TC + NVP <b>or</b> EFV	ABC + ddl + ATV/r	_____
<b>Vietnam (2005)</b>	<b>Adults and adolescents</b>	<p><b>All patients with:</b></p> <ul style="list-style-type: none"> <li>• CD4 count &lt; 200/mm<sup>3</sup> at WHO clinical stage 1 or 2;</li> <li>• CD4 count &lt; 350/mm<sup>3</sup> at WHO clinical stage 3;</li> <li>• WHO clinical stage 4; <b>or</b></li> <li>• WHO clinical stage 2 or 3 with TLC ≤ 1200/mm<sup>3</sup></li> </ul>	d4T <b>or</b> AZT + 3TC + NVP <b>or</b> EFV	ABC <b>or</b> TDF + ddl + LPV/r <b>or</b> SQV/r <b>or</b> NFV	_____

Country (Year)	Clients	Criteria For Starting ARV Treatment	First Line Regimen	Second Line Regimen	Third Line Regimen
Vietnam (2005)	Infants and children	<p><b>Children &lt; 18 months of age with:</b></p> <ul style="list-style-type: none"> <li>• WHO pediatric clinical stage 4 irrespective of CD4%; <b>or</b></li> <li>• WHO pediatric clinical stage 1, 2 or 3 with CD4% &lt; 20%</li> </ul> <p><b>Consider treatment for all children with:</b></p> <ul style="list-style-type: none"> <li>• WHO pediatric clinical stage 3; <b>or</b></li> <li>• WHO pediatric clinical stage 2 with TLC &lt; 2500/mm<sup>3</sup></li> </ul> <p>-----</p> <p><b>Children &gt; 18 months of age with:</b></p> <ul style="list-style-type: none"> <li>• WHO pediatric clinical stage 4 irrespective of CD4% or count; <b>or</b></li> <li>• WHO pediatric clinical stage 1 or 2 with CD4% &lt; 15%</li> </ul> <p><b>Consider treatment for all children with:</b></p> <ul style="list-style-type: none"> <li>• WHO pediatric clinical stage 3; <b>or</b></li> <li>• WHO pediatric clinical stage 2 with TLC &lt; 1500/mm<sup>3</sup></li> </ul>	<p>AZT <b>or</b> d4T + 3TC + NVP <b>or</b> EFV</p> <p>-----</p> <p>AZT <b>or</b> d4T + 3TC + NVP <b>or</b> EFV</p>	<p>ABC + ddl + LPV/r <b>or</b> NFV</p> <p>-----</p> <p>ABC + ddl + LPV/r <b>or</b> NFV</p>	<p>-----</p> <p>-----</p> <p>-----</p>
Zambia (2007)	Adults and adolescents	<p><b>All patients with:</b></p> <ul style="list-style-type: none"> <li>• CD4 count &lt; 200/mm<sup>3</sup>;</li> <li>• WHO clinical stage 4; <b>or</b></li> <li>• CD4 count &lt; 350/mm<sup>3</sup> at WHO clinical stage 3</li> </ul>	TDF + FTC + NVP <b>or</b> EFV	AZT <b>or</b> d4T + 3TC <b>or</b> TDF/FTC + LPV/r	-----

Country (Year)	Clients	Criteria For Starting ARV Treatment	First Line Regimen	Second Line Regimen	Third Line Regimen
Zambia (2007)	Infants and children	<p><b>Clinical Markers</b>  <b>Infants (&lt; 12 months of age) with:</b></p> <ul style="list-style-type: none"> <li>WHO pediatric clinical stage 3 or 4 irrespective of CD4%</li> </ul> <p><b>Immunological Markers</b>  <b>Infants &lt; 11 months of age with:</b></p> <ul style="list-style-type: none"> <li>CD4% &lt; 25% (1500/mm<sup>3</sup>)</li> </ul> <p><b>Children 12 to 35 months of age with:</b></p> <ul style="list-style-type: none"> <li>CD4% &lt; 20% (750/mm<sup>3</sup>)</li> </ul> <p><b>Children 36 to 59 months of age with:</b></p> <ul style="list-style-type: none"> <li>CD4% &lt; 15% (350/mm<sup>3</sup>)</li> </ul> <p><b>Children &gt; 5 years of age with:</b></p> <ul style="list-style-type: none"> <li>CD4% &lt; 15% (200/mm<sup>3</sup>)</li> </ul>	ABC or d4T or AZT + 3TC + NVP or EFV	AZT or d4T + 3TC + ABC	—

For WHO staging information refer to:

- WHO Case Definitions of HIV for Surveillance and Revised Clinical Staging and Immunological Classification of HIV-related Disease in Adults and Children (2007): <http://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf>
  - Table 3: WHO clinical staging of HIV/AIDS for adults and adolescents with confirmed HIV infection (pg. 15)
  - Table 4: WHO clinical staging of HIV/AIDS for children with confirmed HIV infection (pg. 17)

For CDC staging information refer to:

- 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults: <http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm>
- 1994 Revised Classification System for Human Immunodeficiency Virus Infection in Children Less Than 13 Years of Age: <http://www.cdc.gov/mmwr/PDF/rr/rr4312.pdf>
  - Table 1: Pediatric human immunodeficiency virus (HIV) classification (pg. 2)

For more information, please visit [aidstar-one.com](http://aidstar-one.com).

**AIDSTAR-One**

John Snow, Inc.

1616 Fort Myer Drive, 11th Floor

Arlington, VA 22209 USA

Phone: 703-528-7474

Fax: 703-528-7480

Email: [info@aidstar-one.com](mailto:info@aidstar-one.com)

Internet: [aidstar-one.com](http://aidstar-one.com)